Drugs / LEO 152020
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05508776 | Sep → Dec 2022 | — | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04203836 | Jan → Dec 2020 | — | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05117060 | Dec 2021 → Jul 2023 | atopic eczema | JW Pharmaceutical | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-10-20 | JW Pharmaceutical | Results [JW중외제약] 레오파마, 아토피 신약후보물질 권리 JW중외제약에 반환 jw-pharma.co.kr ↗
레오파마는 “레오파마가 진행해 최근 완료된 ‘이주포란트(LEO 152020)’의 글로벌 임상 2a/b상 초기 주요결과에서 일차 평가 지표를 충족하지 못했다”며 알려왔다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-10-20 | JW Pharmaceutical | [JW중외제약] 레오파마, 아토피 신약후보물질 권리 JW중외제약에 반환 jw-pharma.co.kr ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEO 152020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05508776 ↗ |
| Action | Inhibit | “prevent histamine from binding to the receptor” NCT05117060 ↗ |
| Modality | Small molecule | “LEO 152020 is a small drug molecule” NCT05117060 ↗ |
| Route | Oral | “Single oral dose” NCT04203836 ↗ |